PELOSI, NANCY BUYNVDA$500K–$1M—·TUBERVILLE, TOMMY BUYMSFT$50K–$100K—·CRENSHAW, DAN SELLXOM$15K–$50K—·PELOSI, NANCY BUYNVDA$500K–$1M—·TUBERVILLE, TOMMY BUYMSFT$50K–$100K—·CRENSHAW, DAN SELLXOM$15K–$50K—·
K-STREET TRACKER

FOLLOW THE MONEY INTO THE SWAMP

Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.

Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies

💸 Top Spending Clients

#ClientFilingsTotal $
1PFIZER INC.PFE47$46.8M
2GENERAL MOTORS COMPANYGM61$46.8M
3META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA12$44.9M
4VISA INC.V45$37.7M
5AMAZON.COM SERVICES LLCAMZN36$32.8M
6LOCKHEED MARTIN CORPORATIONLMT73$29.0M
7FEDEX CORPORATIONFDX69$27.8M
8ELI LILLY AND COMPANYLLY56$27.1M
9ALTRIA CLIENT SERVICES LLCMO142$25.2M
10AMGEN INCAMGN19$24.9M
11COMCAST CORPORATIONCMCSV179$24.7M
12MERCK & CO INCMRK14$24.0M
13SOUTHERN COMPANYSO53$23.9M
14GOOGLE CLIENT SERVICES LLCGOOGL79$22.6M
15APPLE INCAAPL9$22.1M
16T-MOBILE USA INC.TMUS121$21.0M
17UNITEDHEALTH GROUP INCUNH19$20.4M
18VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ40$20.1M
19OCCIDENTAL PETROLEUM CORPORATIONOXY30$19.7M
20MICROSOFT CORPORATIONMSFT103$18.8M
21QUALCOMM INCORPORATEDQCOM40$17.2M
22GENERAL DYNAMICS CORPGD11$17.0M
23BOEING COMPANYBA23$16.9M
24THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI13$16.9M
25ORACLE CORPORATIONORCL58$16.7M

🎯 Top Lobbied Tickers

#TickerFilingsTotal $
1META
Meta Platforms Inc.
129$50.2M
2PFE
Pfizer Inc.
87$48.6M
3GM
General Motors Company
103$48.4M
4V
Visa Inc.
46$37.7M
5AMZN
Amazon.com Inc.
80$35.3M
6LMT
Lockheed Martin Corporation
88$29.4M
7FDX
FedEx Corporation
82$28.3M
8LLY
Eli Lilly and Company
83$28.1M
9AMGN
Amgen Inc.
95$28.0M
10MRK
Merck & Co. Inc.
92$27.5M
11AAPL
Apple Inc.
64$26.8M
12GOOGL
Alphabet Inc. Class A
123$26.6M
13MO164$26.2M
14SO
Southern Company
108$26.1M
15UNH
UnitedHealth Group Inc.
67$23.9M
16VZ
Verizon Communications Inc.
116$23.8M
17TMUS159$22.7M
18CHTR137$22.6M
19GD
General Dynamics Corporation
127$22.5M
20T
AT&T Inc.
134$21.6M
21ORCL
Oracle Corporation
132$20.6M
22CMCSA
Comcast Corporation
141$20.4M
23CI
The Cigna Group
64$19.9M
24OXY
Occidental Petroleum Corporation
36$19.9M
25MSFT
Microsoft Corporation
122$19.2M

🆕 Filtered Filings · SANOFI U.S.

clear filters
DateTickerClientRegistrantAmountIssue
2026-04-20SNYSANOFI U.S.WILLIAMS AND JENSEN, PLLC$50KGeneral education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. 340B, Vaccine issues. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues; implementation of PL 119-21. Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.
2026-04-19SNYSANOFI U.S.FORBES-TATE$50KIssues related to prescription drug pricing; Issues related to Section 340B of the Public Health Service Act (P.L. 78-410); Drug pricing issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to flu and RSV vaccines. Issues related to prescription drug pricing, including the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Section 340B of the Public Health Service Act (P.L. 78-410); Issues related to pharmacy benefit managers. Issues related to orphan drug tax credit; Issues related to the excise tax for the Vaccine Injury Compensation Fund.
2026-01-20SNYSANOFI U.S.WILLIAMS AND JENSEN, PLLC$50KPolicies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. 340B, Vaccine issues. Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues; implementation of PL 119-21.
2026-01-17SNYSANOFI U.S.FORBES-TATE$50KIssues related to prescription drug pricing; Issues related to Section 340B of the Public Health Service Act (P.L. 78-410); Drug pricing issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to flu and RSV vaccines. Issues related to prescription drug pricing, including the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Section 340B of the Public Health Service Act (P.L. 78-410); Issues related to pharmacy benefit managers. Issues related to orphan drug tax credit; Issues related to the excise tax for the Vaccine Injury Compensation Fund.
2025-10-20SNYSANOFI U.S.WILLIAMS AND JENSEN, PLLC$50KGeneral education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. 340B, Vaccine issues. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues. H.R. 1, One Big Beautiful Bill Act. Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.
2025-10-18SNYSANOFI U.S.FORBES-TATE$50KIssues related to prescription drug pricing; Issues related to Section 340B of the Public Health Service Act (P.L. 78-410); Drug pricing issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to flu and RSV vaccines. Issues related to prescription drug pricing, including the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Section 340B of the Public Health Service Act (P.L. 78-410); Issues related to pharmacy benefit managers. Issues related to orphan drug tax credit; Issues related to the excise tax for the Vaccine Injury Compensation Fund.
2025-07-21SNYSANOFI U.S.WILLIAMS AND JENSEN, PLLC$50KGeneral education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. 340B, Vaccine issues. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues. One Big Beautiful bill. Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.
2025-07-17SNYSANOFI U.S.FORBES-TATE$50KIssues related to prescription drug pricing; Issues related to Section 340B of the Public Health Service Act (PL 78-410); Drug pricing issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to flu and RSV vaccines. Issues related to prescription drug pricing, including the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Section 340B of the Public Health Service Act (PL 78-410); Issues related to pharmacy benefit managers. Issues related to orphan drug tax credit; Issues related to the excise tax for the Vaccine Injury Compensation Fund.
2025-04-21SNYSANOFI U.S.WILLIAMS AND JENSEN, PLLC$50KGeneral education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. American Relief Act (P.L. 118-158). General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. American Relief Act (P.L. 118-158). General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues. Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.
2025-04-16SNYSANOFI U.S.FORBES-TATE$50KIssues related to prescription drug pricing; Issues related to Section 340B of the Public Health Service Act (PL 78-410); Drug pricing issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to flu and RSV vaccines. Issues related to prescription drug pricing, including the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Section 340B of the Public Health Service Act (PL 78-410); Issues related to pharmacy benefit managers. Issues related to orphan drug tax credit; Issues related to the excise tax for the Vaccine Injury Compensation Fund.
2025-01-22SNYSANOFI U.S.WILLIAMS AND JENSEN, PLLC$50KGeneral education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. American Relief Act (P.L. 118-158). General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. American Relief Act (P.L. 118-158). General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues. Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.
2025-01-19SNYSANOFI U.S.FORBES-TATE$50KIssues related to prescription drug pricing, including the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Section 340B of the Public Health Service Act (PL 78-410); Issues related to pharmacy benefit managers. Issues related to orphan drug tax credit; Issues related to the excise tax for the Vaccine Injury Compensation Fund. Issues related to DOD coverage of type 1 diabetes drugs. Issues related to prescription drug pricing; Issues related to Section 340B of the Public Health Service Act (PL 78-410); Drug pricing issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to flu and RSV vaccines; Issues related to DOD coverage of type 1 diabetes drugs.